Background. We evaluated whether diagnostic thyroidectomy for indeterminate thyroid nodules would be more cost-effective than genetic testing after including the costs of long-term surveillance. Methods. We used a Markov decision model to estimate the cost-effectiveness of thyroid lobectomy versus genetic testing (Afirma®) for evaluation of indeterminate (Bethesda 3-4) thyroid nodules. The base case was a 40-year-old woman with a 1-cm indeterminate nodule. Probabilities and estimates of utilities were obtained from the literature. Cost estimates were based on Medicare reimbursements with a 3% discount rate for costs and quality-adjusted life-years. Results. During a 5-year period after the diagnosis of indeterminate thyroid nodules, lobectomy was less costly and more effective than Afirma® (lobectomy: $6,100; 4.50 quality-adjusted life-years vs Afirma®: $9,400; 4.47 quality-adjusted life-years). Only in 253 of 10,000 simulations (2.5%) did Afirma® show a net benefit at a cost-effectiveness threshold of $100,000 per quality-adjusted life-years. There was only a 0.3% probability of Afirma® being cost saving and a 14.9% probability of improving quality-adjusted life-years. Conclusions. Our base case estimate suggests that diagnostic lobectomy dominates genetic testing as a strategy for ruling out malignancy of indeterminate thyroid nodules. These results, however, were highly sensitive to estimates of utilities after lobectomy and living under surveillance after Afirma®.
Thyroid nodules are extremely common and pose a dilemma for surgeons and endocrinologists who seek to avoid unnecessary and costly procedures for their patients. Nearly 50% of adults develop thyroid nodules, and increasing use of cross-sectional imaging has led to a substantial increase in the number of patients undergoing fine-needle aspiration (FNA) biopsy to evaluate thyroid nodules for malignancy.
1,2 Unfortunately, as many as 30% of thyroid nodules will have indeterminate cytology, even though only 5%-30% of these contain cancer. 3, 4 When faced with an indeterminate thyroid nodule, surgeons traditionally have performed a thyroid lobectomy to obtain the definitive, histopathologic diagnosis. Because the vast majority of these procedures reveal benign pathology, many patients are subjected to the risks and costs of an operation without benefit.
One approach to avoid unnecessary thyroidectomy for indeterminate thyroid nodules is the use of molecular testing to identify preoperatively nodules that are likely to be benign. Advocates of molecular testing for indeterminate nodules have emphasized the costeffectiveness of the approach, because a benign result can obviate the need for thyroidectomy. 5 Recent studies and clinical use has focused on a commercially available molecular classifier, Afirma®, that categorizes cytopathology as benign or suspicious on the basis of a proprietary molecular profile. Previous studies have established that Afirma® decreases costs, with the primary benefit being a decrease in the number of thyroidectomies for nodules that are ultimately benign. 6 Cost-modeling for Afirma®, however, was limited to a brief follow-up period that failed to consider the long-term costs of surveillance for thyroid nodules. 7 The purpose of this study is to compare the cost-effectiveness of molecular testing (Affirma®) versus diagnostic lobectomy for indeterminate thyroid nodules.
Methods

Costs and utilities
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Outcomes
Our primary outcome was cost per QALYs, and we assumed a cost-effectiveness threshold of $100,000/QALY. We also tracked secondary outcomes of unnecessary operative procedures, cases requiring long-term hormone replacement, and permanent operative complications. We developed a Markov decision-analytic model to compare thyroid lobectomy with Afirma® testing (Fig 1) .
Base case
The base case was a 40-year-old woman with a 1-cm indeterminate thyroid nodule (atypia of undetermined significance/ follicular lesion of undetermined significance/follicular neoplasm/ Hürthle cell neoplasm). The model assumed that no obvious features concerning for malignancy were present on initial ultrasonography or physical examination (cervical lymphadenopathy, vocal cord paresis, or tracheal or esophageal invasion). We also assumed that final pathology of the operative specimen was always accurate. Parallel arms were constructed to model detected and undetected thyroid cancers (Fig 1) . The 2009 guidelines of the American Thyroid Association (ATA) directed treatment decisions, such that cancers greater than 1 cm detected after diagnostic lobectomy received a completion thyroidectomy. 1 When the Afirma® evaluation returned a "suspicious" result, we assumed 67% of patients underwent total thyroidectomy and 34% underwent an initial lobectomy. For the scenario in which patients had a repeat indeterminate biopsy result, we assumed that 82% would have thyroidectomy rather than continued observation. 2 The model was run in 6-month cycles for a 5-year time horizon. Probabilities, including transition probabilities and complication rates, were obtained from the medical literature and are presented in the Table. Estimates of health state preferences or utilities also came from the literature, and the most widely used preferences are surrogate preferences elicited from a sample of healthcare providers familiar with thyroid disease. 3 The natural history of thyroid cancer, benign thyroid nodular disease, and the mortality data of thyroid cancer were obtained from the literature and the estimates of the Surveillance, Epidemiology, and End Results (SEER) Program of median survival for a 1-cm papillary thyroid cancer for a patient starting at the age of our base case. 31 
Sensitivity analysis
We used a Monte Carlo probabilistic sensitivity analysis with 10,000 replications to derive 95% uncertainty intervals (UIs) for primary and secondary outcomes and incremental cost-effectiveness ratios. Marginal probabilistic sensitivity analysis was used to assess variation in net benefit (assuming willingness to pay of $100,000 per QALY gained) because of uncertainty in each individual parameter value and holding all other parameters fixed at their basecase value. An analysis of threshold sensitivity was conducted for parameters found to affect the overall conclusion of net benefit. Analyses of scenario sensitivity for cost-effectiveness with respect to the primary outcome (QALYs) were conducted, doubling the time horizon to 10 years and assuming that surveillance costs were half their basecase value. Additionally, we conducted an analysis of scenario sensitivity with a 10-year time horizon to assess changes over a longer follow-up period and a 2-way sensitivity analysis that varied the differences in utility estimates and the cost of surveillance. The decision model was programmed in the R language (v 3.3.2) using base functions and the expm package (v 0.999-0) for matrix exponentiation. Recursive partitioning was conducted using the rpart package (v 4.1-10).
Results
Over a 5-year time horizon, the expected incremental cost of Afirma® testing compared with lobectomy was $3,300 (95% UI: $1,100-$5,400), while expected incremental QALYs were −0.03 (95% UI: −0.07 to 0.03). The difference in life-years between the 2 strategies was minimal (4.648 for surgery vs 4.648 for Afirma®). Having greater expected cost and lesser expected QALYs, Afirma® is said to be dominated by lobectomy; the incremental cost-efficiency ratio is undefined (95% UI: dominated to $807,000 per QALY gained), with 253 out of 10,000 Monte Carlo simulations indicating positive net benefit of Afirma® compared with lobectomy, assuming a willingness to pay of $100,000 per QALY gained. This estimate means that in only 2.53% of simulations did Afirma® show a net benefit at a cost-effectiveness threshold of $100,000 per QALY.
Afirma® decreased the probability of an unnecessary thyroidectomy from 76.2% (95% UI: 72.8%-79.4%) to 36.9% (95% UI: 30.9%-43.1%), with cost per unnecessary thyroidectomy averted of $8,400 (95% UI: $2,700-$14,500). Afirma® increased the probability of requiring long-term hormone replacement from 34.7% (95% UI: 31.0%-38.3%) to 49.2% (95% UI: 44.2%-54.4%). Afirma® left the probability of permanent complications unchanged at 2.0% (95% UI surgery: 1.8%-2.2%; Afirma®: 1.7%-2.4%).
Sensitivity analysis
Our primary analysis was based on treatment plans that follow the 2009 guidelines of the American Thyroid Association, but new guidelines were issued in 2015. 4 The new guidelines suggest that lobectomy constitutes adequate treatment for most thyroid cancers in the size range of 1-4 cm, while previous guidelines recommended completion lobectomy for cancers ≥1 cm. To determine whether following the new guidelines would affect our conclusion, we reran the analysis with the assumption that lobectomy would be sufficient treatment for a 1-cm thyroid nodule that was found to be cancer (lobectomy would be both diagnostic and completely therapeutic for the operative strategy; any cancer diagnosed by Afirma® would be treated with lobectomy only). Our sensitivity analysis using the 2015 guidelines found that an Afirma®-based strategy is slightly more effective than operative thyroidectomy(+0.0017 QALYs) but at considerably greater cost (+$3,130) for an incremental cost-effectiveness ratio of $1,843,000. This is substantially greater than the established threshold for costeffectiveness of $100,000 per QALY.
Results of the marginal probabilistic sensitivity analysis for the 10 parameters whose uncertainty has the greatest effect on net benefit (assuming willingness to pay $100,000 per QALY) are shown in Fig 2. The 3 most influential parameters are the differences in utility between the post-lobectomy state and surveillance under Afirma®, the cost of lobectomy, and the cost of Afirma®. The model is sensitive to the post-lobectomy state utility, with net benefit crossing the zero threshold within the 95% UI for that parameter. Threshold analysis determined that, holding all other parameters at their base-case value, if the utility of the post-lobectomy health state (without long-term hormone replacement) is less than 0.954, then Afirma® is expected to be cost-effective at the $100,000 per QALY threshold.
Increasing the time horizon to 10 years had no qualitative effect on the cost-effectiveness of Afirma® compared with lobectomy. The expected incremental cost of Afirma® increased to $5,400 (95% UI: $2,700-$8,500) while the incremental effectiveness of Afirma® decreased to −0.05 QALYs (95% UI: −0.14 to 0.048). Afirma® remained dominated by lobectomy (95% UI: dominated to $635,000 per QALY gained), with 218 of 10,000 Monte Carlo simulations indicating positive net benefit of Afirma® compared with lobectomy, assuming willingness to pay of $100,000 per QALY gained.
Because guidelines for surveillance of nodules classified as benign remain ambiguous, we also varied the intensity of surveillance. We believed that by decreasing the expected cost of surveillance by half to $154.50, which reflected a more relaxed surveillance schedule, also had no qualitative effect on the cost-effectiveness of Afirma® compared with lobectomy. The expected incremental cost of Afirma® decreased to $2,300 (95% UI: $400-$4,100), while the incremental effectiveness of Afirma® was unchanged. Afirma® remained dominated by lobectomy (95% UI: dominated to $659,000 per QALY gained), with 529 out of 10,000 Monte Carlo simulations indicating a positive net benefit of Afirma® compared to lobectomy, assuming willingness to pay of $100,000 per QALY gained.
Finally, we ran a 2-way sensitivity analysis in which the difference in utility between the post-lobectomy state and surveillance under Afirma® was varied along with costs of surveillance (Fig 3) . The incremental net benefit at willingness to pay of $100,000 per QALY was again influenced most heavily by varying the estimate of the utility difference. By contrast, the effect of varying surveillance costs across different utility values had a relatively small effect on the incremental net benefit (Fig 3) .
Discussion
Our primary finding is that diagnostic lobectomy is both more effective and less costly than genetic testing for evaluation of indeterminate thyroid nodules after accounting for the costs of longterm (>5 years) follow-up. The primary appeal of genetic testing (Afirma®) is the ability to avoid under-or overtreatment of indeterminate nodules. If a nodule can be classified correctly as benign, then the patient avoids a thyroidectomy that carries risks with no clear benefit. In contrast, reliance on a genetic test to guide therapy of an indeterminate nodule requires ongoing surveillance to ensure that a malignancy is not being missed. Although the intensity of surveillance is likely to vary among endocrinologists and primary care physicians, the patient will undergo serial ultrasonographic examinations to monitor for growth of the nodule or development of other malignant characteristics. If the nodule enlarges significantly, current guidelines recommend that the patient undergo another FNA evaluation and possibly even a repeat of the genetic test. 4 Our model demonstrates that over a long period, the costs of follow-up and subsequent evaluation eventually exceed the costs of thyroidectomy. Although the short-term costs of thyroidectomy can be high, relatively few long-term costs exist, because definitively diagnosing a nodule as benign obviates the need for further follow-up by ultrasonography.
Thyroidectomy
Another important factor when comparing the cost-effectiveness of thryroidectomy versus genetic testing is the value of utility estimates for various health states associated with each strategy. For lobectomy, decreases in quality of life are related primarily to postoperative complications. Many of these utility estimates are derived from a small sample of healthcare providers or surveys of patients, leaving considerable room for improvement. 9 Additionally, we were unable to find any studies that assessed directly the utilities associated with surveillance after genetic testing of indeterminate thyroid nodules. Instead, we were forced to rely on values based on utilities for patients under surveillance for malignancy or benign nodules. The uncertainty related to valuation of health states after thyroidectomy or genetic testing was reflected in the conclusions from our 2-way sensitivity analysis and marginal probabilistic sensitivity analysis. The modeling of costeffectiveness was highly sensitive to the value of utilities, suggesting that these estimates need to be measured more precisely to compare the 2 treatment strategies. While it is easy to understand how quality of life decreases because of postoperative complications, it is less clear how the uncertainty of long-term surveillance might affect utilities. One could easily imagine that waiting on yearly ultrasonography to evaluate for changes in indeterminate nodules could become stressful and diminish quality of life, but no data on utility or quality of life exist for this health state. Alternatively, patients might place great trust in the results of genetic testing, so serial surveillance may have little effect on their lives as long as they believe in the initial test results. Even in this situation, however, it is possible to have a substantial negative effect on quality of life if tumor neoplasms are missed and allowed to progress over time. While thyroid cancer is generally less aggressive than other malignancies, discovering that a "benign" lesion is actually cancerous can certainly be an unpleasant surprise for patients even if the disease has not progressed. This issue needs to be clarified further before surgeons and endocrinologists firmly commit to either treatment strategy. Our work differs from previous studies that suggested genetic testing was more cost-effective than thyroidectomy for indeterminate thyroid nodules. 7 The most likely reason why we reached a different conclusion was inclusion of the associated surveillance for indeterminate nodules classified as benign. We modeled several different strategies for ultrasonograhic surveillance of a nodule that Marginal probabilistic sensitivity analysis of net-benefit as each parameter is sampled 1,000 times from its probability distribution while other parameters are held constant. Boxes represent the interquartile range of net benefit; vertical bars within boxes represent the median; whiskers represent the 95% UI; and circles represent outliers. The top 10 most influential parameters are presented: u_AL is the utility after lobectomy (including possibility of hormone replacement); u_Surv is the utility of surveillance; u_AT is the utility after thyroidectomy; c_TL is the cost of lobectomy; c_Vera is the cost of the Afirma® test; c_Surv is the cost of surveillance; c_TT is the cost of thyroidectomy; p_specA is the specificity of the Afirma® test; u_Vera is the utility of Afirma® surveillance; and p_STT is the probability of thyroidectomy after suspicious Afirma® result.
was classified as benign by genetic testing, and we considered the possibility that primary care physicians or endocrinologists could order a second genetic test if the nodule changed and FNA biopsy was again indeterminate. We were also able to incorporate more accurate information on the likelihood that a benign nodule would change substantially enough to trigger further evaluation. 8 Equally important, our base case included a 5-year time horizon, but we also evaluated a longer (10-year follow-up) period than the 5-year span examined by Li et al, although a 10-year analysis did not change the underlying conclusions. 7 Because we anticipated that patients with thyroid nodules will have excellent long-term survival, it is important to consider the lifetime costs associated with thyroidectomy versus genetic testing. As more time passes and patients undergo repeat ultrasonography and possibly FNA biopsies, the costs of a genetic testing strategy continue to accumulate. Our approach of examining long-term outcomes is more representative than a short follow-up period after the initial FNA. The most recent ATA guidelines recommended surveillance for at least 2 years, but recommendations for the frequency of surveillance beyond that point remain ambiguous. 4 Finally, we considered the possibility that surgeons who trusted genetic tests might offer patients total thyroidectomy rather than lobectomy for a 1-cm lesion classified as suspicious. We assumed that true believers in genetic testing might regard a test result of "cancer" as equivalent to an FNA showing cancer. Because total thyroidectomy for ≥1-cm cancer is a fairly common choice for operation, many surgeons might opt for upfront total thyroidectomy in this situation. This assumption for the model likely explains how an Afirma®-based strategy could result in more permanent complications and a need for thyroid hormone replacement. Notably, when we varied the rate of total thyroidectomy after a positive Afirma® test, thyroidectomy remained a more costeffective strategy.
Several important limitations of our work should be acknowledged. First, Markov modeling represents an idealized and highly simplified scenario that may not represent costs and outcomes for any particular patient. In the absence of a randomized trial, economic modeling is the only method for comparing strategies for thyroid nodules. Like any economic model, certain assumptions were made, and we acknowledge that we lack modern data for modeling the growth of "missed" cancers for the rare scenario of falsenegative Afirma® results. Additionally, we relied on literature values for utilities, and methodologic issues are present in how these were generated, as we mentioned earlier. More robust efforts to estimate the value of health states associated with thyroidectomy and genetic testing may yield different results. We believe that the proxy utility for a post-lobectomy state of 0.99 may be too high because it does not reflect true complication rates and decision-regret for patients who require thyroid hormone supplementation. The surveillance health state is also poorly understood; surveillance probably imparts some degree of psychologic distress on patients because Within each box, the top number represents the proportion of replications in which Afirma® is cost-effective at a threshold of $100,000 per QALY gained (which can be interpreted as the probability of cost-effectiveness); the bottom number represents the proportion of replications meeting the splitting criteria. u_dif is equal to the utility of Afirma® minus the utility of post-lobectomy (without hormone replacement) health states; u_DL is the utility of detected local cancer health state; and c_TL is the cost of lobectomy.
of repeated cycles of uncertainty and anxiety. Additionally, each surveillance episode represents an economic burden on the patient to take time off of work, obtain an ultrasonography or FNA, and visit the clinic. Because of our own doubts regarding these utility values, our sensitivity analysis included testing the models over a wide range of values for utility, and the vast majority of the simulations indicated that lobectomy was the more cost-effective strategy. We also chose to base our analysis on the 2009 ATA guidelines rather than the 2015 guidelines, because substantial lag time occurs between issuing guidelines and actual practice changes. 32 It should be noted, however, that our sensitivity analysis under conditions defined by the 2015 guidelines still did not indicate that the use of genetic testing was a cost-effective strategy.
In conclusion, after including costs of long-term surveillance, our analysis predicts that diagnostic lobectomy dominates genetic testing as a strategy for ruling out malignancy of indeterminate thyroid nodules. The results, however, are highly sensitive to estimates of utilities, highlighting the need for more rigorous assessment of patient values and preferences to guide decisions about treatment for indeterminate thyroid nodules.
Dr Sareh Parangi (Boston, MA): Thank you very much. I think this is certainly something all of us grapple with at this point in time.
I have one question and one comment. My question is, if the majority of your cost was in surveillance and, if we were to assume that a benign FNA and benign Afirma® were the same, at some point in time that might be provable. I'm not sure it is at this moment. And then following the new ATA guidelines, which they just stopped surveilling, would that, in fact, change your conclusions? Dr Courtney Balentine: So I think it's certainly possible. What I will say is, we modeled various strategies of relaxing and tightening the surveillance, and it didn't significantly affect the results. So, I think from a simulation standpoint, it's hard to make a great argument that it's going to greatly change our conclusions.
The main consideration for me is a more practical one. And, as you know, it's great to publish guidelines. We hope people follow them. But the actual diffusion of guidelines into practice tends to be very slow, especially when there's strong financial incentive to ignore them. And I can't see good reasons why a hospital would give up what's essentially a very easy 5-minute clinic visit and an ultrasound charge when they don't have to. So, there's a lot of pressure, I think, to maintain the surveillance rather than giving up on it. So, it's hard to see that that sort of approach would really make genetic testing strategy more cost-effective rather than less.
Dr Sareh Parangi (Boston, MA): Although I would argue, I mean, we still need to do what's right for the patient and that's why the guidelines come out, and if we're going to take Dr Miyauchi's data, we can watch cancers and not worry about them. I mean, to ignore benign things seems simple.
My other question was, your comment about genetic testing, it's really Afirma®'s gene expression profiling, which is different. I just don't want to confuse it with other tests, which truly are genetic testing. So just to clarify that.
Dr Quan Yang Duh (San Francisco, CA): Very nice study. My question for you is that as you follow the patient and nothing changed, the risk of cancer obviously decreases and is a little bit similar to Sareh's question.
So, in your model, did you take that into account in terms of how often, et cetera? And then related to that question is, this is obviously predicated upon the pretest probability of the cancer. So, you started out probably at 20% because there's a follicular lesion.
To test the model, did you test it at 3%-that is, needle biopsy benign? Maybe the surgeon should just take out the nodule, the thyroid, and it would be more cost-effective.
If that's your conclusion using the model, then I would have a problem with the model. But have you done that? Dr Courtney Balentine: Yes. So, we varied the intensity of the surveillance strategy and allowed for relaxing it, so, for example, we started out with the initial strategy of someone getting an FNA biopsy or an ultrasound like every year to look for changes. And we realized in practice, hopefully people are starting to relax that and not just do it every year or every 6 months.
It didn't really change the conclusion very much mostly because over time, even if you do it only every 2 years or 3 years or 5 years, the costs do start to stack up, especially in the younger patients, and the last talk really highlighted for us, younger patients have different outcomes than older patients just by virtue of the fact that you have to follow them for longer.
And I can certainly imagine scenarios where even if it's every 5 years, it starts out in a 20 or 30 year old and they're 80 and they're still getting ultrasounds every 5 years, it seems kind of harsh to me. So, you know, part of the impetus for doing this, I think, is starting to make a better argument for more rational approach to surveillance.
There's a lot of data out there, but if we can make it in terms of dollars and cents at the hospitals as well as values to the patient, I think we can get a more logical approach to surveillance. And maybe at the end of the day it will become much simpler just to do an upfront test and say you've got this lifetime chance. It's totally fine to check it every 5 years, you will be okay, or every 10 years, don't worry about it.
Dr Quan Yang Duh (San Francisco, CA): The pretest probability? Dr Courtney Balentine: We varied the pretest probability initially. We didn't consider benign. We just looked at indeterminant. So, we are rerunning the simulations now specifically to look at FLUS and AUS rather than Follicular NEO or Hürthle cell NEO. My suspicion is that's going to make surgery actually even more costeffective just because, again, it's not going to become cancer anytime soon, and surveillance costs are going to start to add up. You trade that off with the changes in guidelines saying that now you don't need to do a total thyroidectomy for these patients anymore, so the complication rate for surgery goes down. If you're just doing a lobe, the surveillance costs stay pretty similar for the same genetic test up front.
Dr Quan Yang Duh (San Francisco, CA): Run it for the benign, too, so that you can compare that.
Dr kyle a. Zanocco (Los Angeles, CA): So, I was surprised to see that there was a lower quality-adjusted life expectancy with the gene expression classifier and surveillance strategy compared to just doing the lobectomy. And my question is related to Dr. Duh's. Why do you think that was the case? Why was the utility lower for a patient undergoing surveillance versus undergoing the potential morbidity of a diagnostic procedure? Dr Courtney Balentine: Sure. I think part of it has to do with relative morbidity from surgery. You know, you never want to trivialize it and obviously say that there's not huge change.
As the complication rates go down, the relative utility for a lobe compared to a total, compared to surveillance, starts to diminish significantly. At the same time, you have to consider what's going on during the surveillance state. So, there's not great data, unfortunately, right now for us to say "under conditions of surveillance following a genetic test." This is where the patient is sitting in terms of their estimated value for that health state. So, we had to vary it a fair amount to see. And it's completely possible that we messed that up, because there's not great data for it right now. So, I think one of the things that we want to do is more definitively study that and then come back and see, are we somewhere in the ball park or not. And I don't have a great answer for that at this point.
